Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update

Achieved Record Q2 2023 Total Net Revenues of $99.6 MillionAchieved FIRDAPSE® 2023 Second Quarter Net Revenues of $64.9 Million, a 22% Increase YOYAchieved 2023 Second Quarter GAAP EPS Diluted of...

Related Keywords

Japan ,China ,United States ,Canada ,South Korea ,America ,American ,Dydo Pharma ,Patrickj Mcenany ,Tamar Thompson ,Devices Agency ,Company Quarterly Report On Form ,Exchange Commission ,Catalyst Pharmaceuticals ,Development Expenses ,Health Canada ,International Number ,Company Nasdaq ,Catalyst Pharmaceuticals Inc ,Santhera Pharmaceuticals ,Net Revenues ,Quarter Net Revenues ,North American License ,Maximum Indicated Dose ,Full Year ,Revenue Guidance ,North American ,Three Months Ended June ,Income Per Share ,Post June ,Medical Devices Agency ,Second Quarter ,Administrative Expenses ,Intangible Assets ,Cash Equivalents ,Quarterly Report ,Canada Dial In Number ,Dial In Number ,North America ,Fast Track ,Full Prescribing ,Safety Information ,Full Prescribing Information ,Annual Report ,Markets ,